DashboardAll companies
Run this on your own research
Healthcare · Medical Distribution

Hanmi Science Co., Ltd.

008930KRX₩43,100+₩900 (+2.13%)Market closed

Price Chart

Daily

Key facts

Market Cap
₩2.95T
P/E
24.7x
P/B
3.03x
ROE
13.1%

Hanmi Science Co., Ltd.

Healthcare · Medical Distribution · FY 2025

Hanmi Science Co., Ltd. is a prominent South Korean company engaged in the pharmaceutical and biotechnology sectors, with a focus on developing innovative healthcare solutions. As the holding company of Hanmi Pharmaceuticals, its primary function is to drive drug discovery and ensure the availability of effective medical products. Hanmi Science undertakes research and development activities, emphasizing biopharmaceuticals and chemical drugs, particularly in areas like oncology, diabetes, and autoimmune diseases. The company plays a vital role in the healthcare industry by advancing medical research and contributing to improving public health outcomes. Operating as a key player within the biotechnology market, Hanmi Science influences the proliferation of cutting-edge therapies and medicines, both in South Korea and internationally. Its commitment to innovation and therapeutic advancements has positioned it as a critical contributor to the global pharmaceuticals landscape, impacting not only direct healthcare provision but also broader industry research collaborations and partnerships.

CEO
김재교
Employees
443

Company Statistics

Valuation

P/E
24.7x
P/B
3.03x
P/S
2.15x
EV/EBITDA
19.7x
P/FCF
109.1x

Margins

Gross
23.3%
EBITDA
11.2%
Operating
4.2%
Pre-Tax
9.8%
Net
8.7%

Returns

ROA
8.3%
ROE
13.1%
ROIC
10.1%

Growth (CAGR)

Rev 3Yr
9.1%
Rev 5Yr
9.6%
Op Inc 3Yr
26.5%
Net Inc 3Yr
19.5%

Financial Health

Cash & Cash Equivalents
₩127.39B
Net Debt
₩402.46B
Debt/Equity
55.2%
Interest Cov
—

Profile

Revenue
₩1.36T
Shares Out
68.4M
Public markets · Korea, US, Japanalpha-lenz.com · Core by Treasurer
Hanmi Science Co., Ltd. (008930) Stock Forecast 2026 ₩43,100 — Price, Financials & Analyst Targets | AlphaLenz